| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Director | Common Stock | 39.8K | $132K | $3.31 | Jun 3, 2025 | Direct |
| Avalo Therapeutics, Inc. | Chief Executive Officer, Director | Stock Option (Right to Buy) | 78.1K | Oct 1, 2021 | Direct | ||
| Phathom Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 17.5K | Jun 3, 2025 | Direct | ||
| Sage Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 0 | Jul 31, 2025 | Direct |